ZAGREB, March 5 (Hina) - Croatia's drugs company Pliva wrapped up 2002 successfully, marking a 21.7 percent revenue increase in the domestic currency and a 29 percent increase in USD, as well as a 26.5 percent profit per share in
kunas and 35 percent in USD, management board member Dubravko Mak said on Wednesday.
ZAGREB, March 5 (Hina) - Croatia's drugs company Pliva wrapped up
2002 successfully, marking a 21.7 percent revenue increase in the
domestic currency and a 29 percent increase in USD, as well as a 26.5
percent profit per share in kunas and 35 percent in USD, management
board member Dubravko Mak said on Wednesday. #L#
The company's supervisory board decided yesterday to propose to the
shareholders' meeting in May the payment of a 17 kuna stock
dividend, which is 13 percent more that in 2001, said Mak, adding
this was the highest dividend proposed for payment.
Last year the Pliva Group made 6.4 billion kuna ($914.3 mln) in
revenue, of which almost 50 percent from the sale of prescription
drugs -- 3.48 billion kuna. Revenue from international markets
accounts for 81.9 percent of total revenue, an increase of 6.4
percent, said Mak.
Broken down by regions, the majority of the revenue was generated in
Central and East Europe -- 2.89 billion kuna ($412.9 mln) -- while
the highest revenue increase -- 38.5 percent -- was recorded in
North America where, after Pliva bought the Sidmak company, it
reached 2.32 billion kuna ($331.4 mln).
Pliva's investments last year totalled a record-high 1.8 billion
kuna ($257.1 mln), of which 1.2 billion ($171.4 mln) went into
acquisitions.
Pliva's assets are worth 9.87 billion kuna ($1.41 bln).
($1 = 7 kuna)
(hina) ha sb